Former Senior Vice President, Chief Commercial Officer · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Remy Sukhija

A named executive officer of MADRIGAL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$7,362,378

Salary $387,718Stock awards $4,500,000

FY2022: $3,510,849

3rd of 7 named executive officers at Madrigal Pharmaceuticals by FY2023 total.

7 named officers on file for MADRIGAL PHARMACEUTICALS, FY2023

Remy Sukhija’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • MDGL’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how MADRIGAL PHARMACEUTICALS’s whole pay program stands against its peers

  • MADRIGAL PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MDGL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Remy Sukhija’s full pay file as a PDF — free

More than this page: up to 10 years of Remy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Remy Sukhija compensation by year

MADRIGAL PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$337,500$461,250$482,813$387,718
Bonus$100,000$0$0$0
Stock awards$0$0$0$4,500,000
Option awards$2,724,000$2,048,400$2,725,650$0
Non-equity incentive$274,680$248,436$292,005$0
Pension and deferred compensation$0$0$0$0
All other$2,722$10,381$10,381$2,474,660
Total$3,438,902$2,768,467$3,510,849$7,362,378

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 29, 2024, accession 0001193125-24-122657, and prior-year filings. Open the filing on EDGAR.

How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001193125-24-122657. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$3.4M
$2.8M
$3.5M
$7.4M
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option60,000—$60.26

Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

MADRIGAL PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Bill SiboldPresident and Chief Executive Officer$32,268,400
Paul FriedmanFormer Chief Executive Officer$9,563,286
Remy Sukhija · this pageFormer Senior Vice President, Chief Commercial Officer$7,362,378
Rebecca TaubPresident, Research & Development and Chief Medical Officer$6,928,008
Brian LynchFormer Senior Vice President and General Counsel$5,266,584
Alex HowarthFormer Senior Vice President and Chief Financial Officer$5,262,023
Carole HuntsmanChief Commercial Officer$3,142,354

The full MADRIGAL PHARMACEUTICALS compensation record

free company brief

This page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Remy Sukhija's compensation dossier · One-time report. No refunds.